Exciting AI-Facilitated Novel PHD1/2 Inhibitor Targeting Gut Healing Pathways Shows Favorable Safety скачать в хорошем качестве

Exciting AI-Facilitated Novel PHD1/2 Inhibitor Targeting Gut Healing Pathways Shows Favorable Safety

Exciting AI-Facilitated Novel PHD1/2 Inhibitor Targeting Gut Healing Pathways Shows Favorable Safety Profile in the Phase I Studies for IBD The Breakthrough:Enter the new class of drugs: oral, gut-restricted PHD1 & PHD2 dual inhibitors. Because these drugs act only in the gut, they offer the potential to harness the healing benefits of HIF activation exactly where IBD patients need it—without systemic exposure and its risks. Background:As we know, Inflammatory Bowel Disease is marked by chronic inflammation of the colon and small intestine, leading to ongoing wounding of the gut lining and a breakdown of the epithelial barrier. This barrier loss is a key problem, contributing to symptoms and complications in both UC and Crohn’s. The Science Bit:Recently, researchers have highlighted the protective role of Hypoxia-Inducible Factors (HIFs) in IBD. When activated, HIFs trigger genes that help heal and protect the gut barrier. Normally, the body uses proteins called prolyl hydroxylases (PHDs—specifically PHD1 & PHD2) to mark HIFs for breakdown. But if you inhibit these PHDs, HIFs stick around longer, boosting the barriers that prevent inflammation and promoting healing. Why Not Just Block PHDs for Everyone?Here’s where it gets tricky. Broadly blocking PHDs everywhere in the body could lead to side effects like increased cancer risk, eye problems, high blood pressure, and more—since HIFs are involved in tons of biological processes throughout the body. What This Means: • Enhanced epithelial barrier healing 🛡️ • Reduced gut inflammation • Lower potential for whole-body side effects 🔬